U.S. License Holder:
GlaxoSmithKline
Date of License:
August-05-2020
Last Update:
Dec-15-2024
FDA-Approved Indications
BLENREP (belantamab mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.